Objectives

  1. To provide an open forum enabling discussion and recommendations on the FDA Draft Guidance for Industry: Abuse Deterrent Opioids – Evaluation and Labeling
  2. To provide an opportunity for presentations by experts addressing the Draft Guidance

 

Abuse Deterrent Formulation Science Meeting 

Discussion of the FDA Draft Guidance for Industry: Abuse Deterrent Opioids – Evaluation and Labeling

 

  • Organized by the Cross Company Abuse Liability Consortium (CCALC)

  • Facilitated with the aid of the College on Problems of Drug Dependence (CPDD)

  • With presentations by the FDA representatives 

Agenda

Objectives

  1. To provide an open forum enabling discussion and recommendations on the FDA Draft Guidance for Industry: Abuse Deterrent Opioids – Evaluation and Labeling

  2. To provide an opportunity for presentations by experts addressing the Draft Guidance  

List of Speakers